Abstract: HAS is a superantigen extracted from staphylococcus aureus metabolite. Studies have shown that through activating T cells and natural killer cells, enhancing phagocytes' phagocytosis and killing ability of lymphocytes, increasing leucocyte count in peripheral blood, and repairing impaired histiocytes, HAS can improve the immune function and inhibit the growth of tumor cells. Intracavitary perfusion of HAS is effective for malignant ascites. Combination with chemotherapeutics, HAS can remarkably improve ascites elimination coefficient. It can also enhance the effect of radiotherapy and decrease the side effects of radiotherapy. HAS is mainly used to treat malignant tumor, leucocytopenia and malignant ascites. This review summarized the clinical application of highly agglutinative staphylococcin (HAS) in cancer treatment based on about 100 papers published in China.